Usona Institute
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Psilocybin for Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 240
- Registration Number
- NCT06308653
- Locations
- 🇺🇸
University of Alabama Clinical Research Unit, Birmingham, Alabama, United States
🇺🇸Preferred Research Partners-NWA, LLC, Fayetteville, Arkansas, United States
🇺🇸Preferred Research Partners, Inc., Little Rock, Arkansas, United States
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers
- Conditions
- PharmacokineticsSafetyTolerability
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 54
- Registration Number
- NCT05698095
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
- Conditions
- QTc IntervalPharmacokinetics
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05478278
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04353921
- Locations
- 🇺🇸
Segal Trials, Lauderhill, Florida, United States
A Study of Psilocybin for Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 104
- Registration Number
- NCT03866174
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Pacific Neuroscience Institute, Santa Monica, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
News
Psilocybin Shows Promise in Easing End-of-Life Distress
• Psilocybin-assisted therapy is emerging as a potential treatment for anxiety, depression, and existential distress in patients facing terminal illnesses. • Studies show that psilocybin can significantly reduce depression and anxiety in cancer patients, with benefits lasting for six months or longer. • Psilocybin influences the brain's default mode network, reducing rumination and fear of death, and fostering a sense of peace and acceptance. • The FDA has granted Breakthrough Therapy status to psilocybin for depression-related conditions, accelerating its development and review for potential palliative care applications.
FDA Rejects MDMA for PTSD Treatment, Raising Questions for Psychedelic Therapies
The FDA has declined to approve MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD), requesting an additional late-stage study.